Bortrac 2 mg Injection
  1. Home
  2. Pharma Products
  3. Glenmark Pharmaceuticals Ltd
  4. Bortrac 2 mg Injection

Bortrac 2 mg Injection

Bortrac 2 mg Injection contains bortezomib 2 mg and is an anticancer medicine used in the treatment of multiple myeloma and mantle-cell lymphoma. It is supplied as a single-vial presentation and is administered by a qualified healthcare professional according to the prescribed treatment protocol. Bortezomib works by inhibiting proteasomes, which disrupts protein processing in cancer cells and can slow their growth.

BUY NOW

Category

Bortrac belongs to the proteasome inhibitor class of anticancer medicines and is used as part of appropriate oncology treatment regimens. By blocking proteasome activity, bortezomib causes disruption of cellular protein balance and promotes the death of susceptible malignant cells. The medicine is administered by injection under medical supervision, with the dose and schedule determined according to the patient’s condition and treatment protocol. Blood counts and other clinical parameters may need monitoring during treatment because bortezomib can cause thrombocytopenia, neutropenia, fatigue, gastrointestinal effects, and peripheral neuropathy.

Technical Specification

Specification Details
Active Ingredient Bortezomib
Strength 2 mg
Dosage Form Injection
Pack Size 1 vial
Therapeutic Class Antineoplastic
Manufacturer/Marketer Glenmark Pharmaceuticals Ltd

Product Also Known As

Bortrac 2mg Injection, Bortrac 2mg Vial, Bortezomib 2mg Injection, Bortezomib 2mg Vial, Bortezomib Injection 2mg, Bortezomib Proteasome Inhibitor Injection